Remove 2025 Remove Biosimilars Remove Pharmacy
article thumbnail

The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market

Drug Channels

The 2025 launch of biosimilars to Johnson & Johnson’s Stelara (ustekinumab) marks another turning point in pharmacy benefit dynamics. But unlike the chaotic rollout of Humira biosimilars, pharmacy benefit managers (PBMs) came prepared. As always, with great pricing power comes great responsibility.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

Biosimilars and Generics : Where cost competition necessitates strategic brand differentiation and efficient coverage. OTC and Consumer Health Products : Brands in this segment benefit from lean, geographically dispersed sales forces that focus on brand visibility and pharmacy-level engagement.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DEA Pharmacy Decision Highlights Agency’s Thinking on Expert Credibility and Testimony, as well as Red Flag Resolution

FDA Law Blog: Biosimilars

Hull A recent DEA decision revoking the registration of a Louisiana pharmacy sheds light on the Agencys approach to crediting one experts testimony over that of another expert during an administrative hearing. In Neumanns Pharmacy, LLC , 90 Fed. By Andrew J.

article thumbnail

Prescribing Red Flags: Pharmacists Be Wary of What the Doctor Orders

FDA Law Blog: Biosimilars

Attorneys Office, Northern District of Illinois, April 21, 2025. Patients filling prescriptions at the same time at multiple pharmacies. Patients traveling long distances to the prescriber and/or to the pharmacy. Houck Last month the U.S.

Doctors 65
article thumbnail

The Big Three PBMs’ 2025 Formulary Exclusions: Humira, Stelara, Private Labels, and the Shaky Future for Pharmacy Biosimilars (rerun)

Drug Channels

Click here to see the original post from January 2025. For 2025, the three largest pharmacy benefit managers (PBMs)Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)have again each excluded hundreds of drugs from their standard formularies. What do you think? All rights reserved.

article thumbnail

The Top Pharmacy Benefit Managers of 2024: Market Share and Key Industry Developments (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. Click here to see the original post from March 2025. Three’s still company in the world of pharmacy benefit managers. All rights reserved.

article thumbnail

Drug Channels News Roundup, March 2025: PBM Unbundling Update, Stelara Biosimilar Price War, My $0.02 on the Optum Rx News, Follow the Dollar, and #DCLF2025

Drug Channels

on April 4, 2025, from 12:00 p.m. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Coming soon: PBM Industry Update: Trends, Challenges, and Whats Ahead.Our first webinar of the year will tackle the most controversial drug channel participants. Join Adam J. Fein, Ph.D., to 1:30 p.m.